Form 4: Repligen Corp Director Martin D. Madaus Reports Acquisition of Restricted Stock Units and Stock Options

Director Martin D. Madaus reported the acquisition of 701 restricted stock units and 1,376 stock options in Repligen Corp on May 16, 2024.

Summary

• On May 16, 2024, Martin D. Madaus, a director of Repligen Corp, acquired 701 restricted stock units (RSUs) and 1,376 stock options.
• The RSUs represent a contingent right to receive one share of Repligen Corporation's Common Stock each.
• These RSUs vest on the earlier of May 16, 2025, or the date of the next annual meeting of the Company's shareholders.
• The stock options have an exercise price of $171.03 and also vest on the earlier of May 16, 2025, or the date of the next annual meeting of shareholders, expiring on May 16, 2034.
• Following these transactions, Mr. Madaus directly owns 2,998 shares of common stock and indirectly owns 11 shares through a spouse's trust, along with 1,376 stock options.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The acquisition of stock options and restricted stock units by a director generally indicates confidence in the company's future, but it's a routine transaction.

Positives

• The acquisition of restricted stock units and stock options by a director signals confidence in the company's future performance.

Future Outlook

The vesting of the restricted stock units and stock options is contingent upon the earlier of May 16, 2025, or the date of the next annual meeting of the Company's shareholders, which has not yet been determined.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders, such as directors and officers. These filings are closely watched by investors to gauge management's sentiment and confidence in the company's prospects.

Comparison to Industry Standards

• Stock option and RSU grants are a common form of compensation for directors and executives in publicly traded companies, particularly in the biotech and pharmaceutical industries.
• Companies like Thermo Fisher Scientific, Danaher, and Sartorius also utilize similar equity-based compensation plans to align the interests of management with those of shareholders.
• The vesting schedules and exercise prices are generally in line with industry standards, designed to incentivize long-term value creation.

Stakeholder Impact

• The acquisition of equity by a director can positively impact shareholders by aligning management's interests with theirs.
• Employees may view this as a positive sign of company stability and growth potential.

Key Dates